Verdict No. 3062 · Search date 2026-09-08 · Methodology v1.0
Single-ingredient garlic tablets 900 mg/day; powder, processing, and active-constituent specifications unverified,
does it really help with Reduction of HbA1c in adults with type 2 diabetes?
30-Second Summary
C
Evidence Grade C · 46 · Safety caution
Only 24-week HbA1c with the 900-mg/day tablet is judged; fasting glucose, insulin, lipids, and complications are separate.
Caution. Monitor hypoglycemia with glucose-lowering therapy and review gastrointestinal effects, bleeding risk, and product-content variation.
What the
research showsGrade C with 46 points. The 900-mg/day primary report found statistical significance at 24 weeks, but the dose-specific absolute percentage-point contrast, 95% CI, completion denominator, and prespecified primary hierarchy are unverified. A 2026 pooled WMD of -0.50 percentage points (95% CI -0.66 to -0.33; I²=96.4%) mixed formulations and background treatments and does not establish this tablet's effect.
research showsGrade C with 46 points. The 900-mg/day primary report found statistical significance at 24 weeks, but the dose-specific absolute percentage-point contrast, 95% CI, completion denominator, and prespecified primary hierarchy are unverified. A 2026 pooled WMD of -0.50 percentage points (95% CI -0.66 to -0.33; I²=96.4%) mixed formulations and background treatments and does not establish this tablet's effect.
What the
ads claimThis cannot support replacing diabetes medicine, preventing complications, or claiming the same effect for all garlic foods.
ads claimThis cannot support replacing diabetes medicine, preventing complications, or claiming the same effect for all garlic foods.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Raw garlic, powder, garlic oil, stabilized-allicin products, aged garlic extract, black garlic, fermented garlic, and isolated S-allylcysteine are not interchangeable.
- Caution. Monitor hypoglycemia with glucose-lowering therapy and review gastrointestinal effects, bleeding risk, and product-content variation.
Chamgap Semantic Classification Code
Permanent code issued
S.garlic-tablet.oral.hba1c.reduce.placeboSupplements and nutraceuticals > Single-ingredient garlic tablet > Oral > HbA1c > Reduction claim > Placebo
Issued only for HbA1c in type 2 diabetes with the 900-mg/day tablet; fasting glucose, insulin, weight, and lipids are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Single-ingredient garlic tablets |
| Source or part used | Preparation derived from Allium sativum L. cloves |
| Formulation or processing | Single-ingredient garlic tablets; powder, processing, and alliin/allicin specifications unverified |
| Route | Oral |
| Dose | Selected 900 mg/day; individual dose and schedule unverified |
| Duration | 24 weeks of treatment with measurements at weeks 12 and 24 |
| Population | Adults with established type 2 diabetes; common stable background medication unverified |
| Effect or condition | Lower absolute HbA1c |
| Primary endpoint | Between-group absolute HbA1c change at week 24 |
| Comparator | Placebo tablets; metformin was a separate active arm |
| Duplicate-detection key | Single-ingredient garlic tablets|Single-ingredient garlic tablets; powder, processing, and alliin/allicin specifications unverified|Oral|Adults with established type 2 diabetes; common stable background medication unverified|Lower absolute HbA1c|24 weeks of treatment with measurements at weeks 12 and 24 |
Gap Measurement · Verdict 3062 · C 46
What the research actually shows
The seven-arm primary report with the selected 900-mg tablet was kept separate from two current meta-analyses, and other formulations and background-treatment details were not transplanted.
Why this is classified as C (46)
No strength is confirmed; S and EX apply, and uncertainty in the selected effect, denominator, and funding is not rewarded, yielding C/46.
Counterpoint. A separate 2026 GRADE meta-analysis also estimated about -0.53 percentage points but concluded that further high-quality RCTs are needed.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effects of garlic on blood glucose levels and HbA1c in patients with type 2 diabetes mellitus | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 30 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| The Therapeutic Effect of Garlic Supplements on the Metabolic Profile of Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 7 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| Effects of garlic supplementation on glycemic indices in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 1,619 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-09-08).
Ebrahimzadeh A et al. Nutr Metab Insights. 2026. PMID: 41695233. DOI: 10.1177/11786388251413660. PROSPERO CRD42024628780.
checkedAlsanie SA et al. Diabetes Res Clin Pract. 2026;239:113407. PMID: 42398591. DOI: 10.1016/j.diabres.2026.113407.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Garlic Tablets for HbA1c—A Positive Signal Without a Verified Absolute Effect for the Selected 900-mg Formulation — Evidence Grade C·46. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/oral-garlic-type-2-diabetes-hba1c/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.